Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)-Reference-Cited by-同舟云学术

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

Published:2021-12 Issue: Volume:162 Page:9-15
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Popat Sanjay,Jung Hyun Ae,Lee Shin Yup,Hochmair Maximilian J.,Lee Seung Hyeun,Escriu Carles,Lee Min Ki,Migliorino Maria R.,Lee Yong Chul,Girard Nicolas,Daoud Hasan,Märten Angela,Miura Satoru

Funder

National Institute for Health Research

Institute of Cancer Research

Boehringer Ingelheim International GmbH

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations;Shah;Clin. Lung Cancer.,2020

2. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial;Paz-Ares;Ann. Oncol.,2017

3. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol.,2016

4. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial;Wu;Lancet Oncol.,2017

5. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations;Mok;J. Clin. Oncol.,2018

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC;ESMO Real World Data and Digital Oncology;2024-09

2. New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors;American Society of Clinical Oncology Educational Book;2024-06

3. Optimal First-Line Treatment for EGFR-Mutated NSCLC: A Comparative Analysis of Osimertinib and Second-Generation EGFR-TKIs;2024-01-22

4. Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC;Therapeutic Advances in Medical Oncology;2024-01

5. Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data;Translational Lung Cancer Research;2023-11